Fondaparinux Market Set to Reach USD 2.5 Billion by 2032, Growing at a CAGR of 6.8%
Introduction Fondaparinux Market a synthetic anticoagulant classified as a factor Xa inhibitor, is widely used for the prevention and treatment of thromboembolic disorders such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Its efficacy, predictable pharmacokinetics, and low risk of heparin-induced thrombocytopenia have contribut